rate in Biological Technology

BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase

NEWARK, N.J., July 9 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that at ATS Labs, using a Quantitative Disk Carrier test starting with 5.5 million Clostridium Difficile (C.diff) spores...

Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US

Even Among Companies Doing Well, Relationships Weaken in Many Countries NEW YORK, Feb. 17 /PRNewswire/ -- New TNS Healthcare research shows that physicians in four out of the five major European countries -- the UK, Germany, Spain and Italy -- give Novartis top marks for effectively deliverin...

deCODE Sells Auction Rate Securities

REYKJAVIK, Iceland, Jan. 20 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) announced today that it has entered into an agreement with NBI, an Icelandic financial institution, pursuant to which NBI has purchased deCODE's auction rate securities for an aggregate price of $11 million. Pu...

National Ergonomics Expo Sees 86% On-Site Exhibitor Renewal Rate for 2009; New Products from Contour Design, Equipois, Goldtouch and Herman Miller Win 2008 NECE Attendees' Choice New Product Awards

NEW YORK, Dec. 10 /PRNewswire/ -- The 14th Annual National Ergonomics Conference and Exposition (NECE) at Caesars Palace, Las Vegas, Dec. 2 - 5 was yet again the largest annual gathering of ergonomics decision makers and ergonomics product sellers held in the U.S. with over 1,200 attendees represe...

Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics

REHOVOT, Israel and JERSEY CITY, New Jersey, October 27 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG ), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that Credit Suisse, as part of a settlement agreement it has reached with the Att...

Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014

VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that in connection with the previously announced tender offer (the "Tender Offer") for its outstan...

China Medical Technologies Adjusts Conversion Rate of Convertible Notes

BEIJING, July 25 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy sy...

Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014

VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the commencement of a cash tender offer of the outstanding notes listed below (the "Notes") in an a...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

Results of phase I/II study highlighted in oral presentation at conference on malignant lymphoma LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II ...

Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance

SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its ave...

Group Hotel Rate Ends Friday: Reserve Now for Leadership Development Conference June 4-6

CHAPEL HILL, N.C., May 7 /PRNewswire/ -- Building a comprehensive and coherent corporate brand and positioning that attracts talent from the competitive marketplace is a critical step to developing a pipeline of potential high-performers. This plus recruiting, developing, retaining and engagin...

Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity

GENEVA, Switzerland, March 10 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. T...

National Ergonomics Conference and Expo Reaches 94% Exhibitor Renewal Rate

New November 17 - 20, 2009 Dates Announced Ergonomics Programs Prove Vital in a Slow Economy NEW YORK, March 5 /PRNewswire/ -- The 15th Annual National Ergonomics Conference and Exposition (NECE) will be held at Caesars Palace, Las Vegas, November 17 - 20, 2009. As of today, nearl...

China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate

TAIAN CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (''China Biologic'' or the ''Company''), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (''PRC''), today announced that the Company's i...

Transplant Program Tops in Expected One-Year Survival Rate

SEATTLE, Jan. 22 /PRNewswire/ -- Fred Hutchinson Cancer Research Center's stem-cell transplant program at the Seattle Cancer Care Alliance (SCCA) was one of only two transplant programs nationwide that consistently outperformed the expected one-year survival rate for unrelated donor transplant...

China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate

HARBIN, China, Jan. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that thre...

Customers Rate Epic as Best Overall Vendor in Healthcare for Seventh Consecutive Time

MADISON, WI - KLAS Enterprises, a research and consulting firm based in Draper, UT, named Epic Systems Corporation Best Overall Vendor in its Top 20 Year-end Report Card. The study, which included 200 vendors, was based on a confidential survey of CIOs, executives, managers, and clinicians represe...

DHEA Boosts Growth Rate of Human Neural Stem Cells

MADISON - Human neural stem cells, exposed in a lab dish to the steroid DHEA, exhibit a remarkable uptick in growth rates, suggesting that the hormone may play a role in helping the brain produce new cells, according to a new study published this week in the online editions of the Proceedings of th...

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

...ed Gestiva(TM) acquisition agreement; (20) the possibility that the auction rate securities held by the Company may not return to liquidity at their face va...le or licensing of certain assets; (27) the ability to monetize the auction rate securities (ARS) currently held by the Company, the amount of proceeds to b...

Schering-Plough Shareholders Approve Merger With Merck

...cts and pipeline projects; market forces; economic factors such as interest rate and exchange rate fluctuations; the outcome of contingencies such as litigation and investiga...

Novavax Reports Second Quarter 2009 Financial Results

...ing convertible notes. The notes carried a coupon rate of 4.75% payable semi-annually and had a maturity ....5 million related to one of the company's auction rate securities due primarily to its continued illiquid...cash and short-term investments (including auction rate securities recorded at their fair value) as compar...

NeurogesX Reports Second Quarter 2009 Results

...ent for end-users of Qutenza; the tolerability profile and/or benefits of NeurogesX' product candidates; expectations regarding expenses and cash burn rate as well as receipt of any payments from partners; ability to secure adequate or additional financing; and the sufficiency of cash resource to fund the...

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

...ts, and, thereafter until maturity, at any time. The notes will be convertible by holders into shares of Onyx's common stock at an initial conversion rate of 25.2207 shares of common stock per $1,000 principal amount of notes (subject to adjustment in certain circumstances), which represent an initial co...

Microbix Sales Grow 22% For Nine Months

... Burn rate significantly reduced and Semen Sexing Technology achieves milestone ...ntinues its corporate restructuring to conserve cash and eliminate its burn rate in order to ensure its pipeline products reach their full potential. The gr...

ThermoGenesis Provides Update on Fiscal 2009 Results

... bone marrow aspirate to concentrate stem cells, was formally launched in July. The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Company also announced today, in a separate press release, an expanded collaboration agreement with Celling Techno...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

...on, which includes approximately $12 million in non-cash FAS 123R expenses. Cash burn of approximately $52 to $57 million. The increase in burn rate is due to increased legal expenses, and increased expenses associated with the ramp up of the company's diagnostics efforts. About...

OncoGenex Reports Second Quarter 2009 Financial Results

...The unadjusted hazard ratio (HR), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with OGX-011. - Preliminary results of a phase 1 trial of OGX-427 were presented during an oral pres...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...as in the United States. The average gross royalty rate earned in the three month period ended June 30, 20...achieved in 100% of the subjects and the retrieval rate in the study was 92.3%. Clinical success, which wa...ertain exceptions, will bear interest at an annual rate of 10%, compounded quarterly, and will have a term...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

...eceivable of $13.4 million, as compared to $15.5 million at December 31, 2008. In addition, at June 30, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments. Additionally, in July 2009, the Company received $2.75 million of cash from a settlement wi...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour urine protein). Additionally, the FDA and Amicus reached agreement on an improved methodology for the histological evaluation...

TSH Testing Raises Awareness of Importance of Thyroid Health

...no standard testing programs for thyroid health in the U.S. even though the rate of thyroid cancer has nearly tripled since 1980," said Joseph Mangano, MPH,...our counties neighboring Indian Point, thyroid cancer is 70% above the U.S. rate and newborn hypothyroidism, a cause of mental retardation, is 90% greater t...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... State tax regime, which lowered the effective tax rate in Q2 2009 compared to Q2 2008. Using a full year expected effective tax rate of 24%, Non GAAP diluted earnings per ADS fo...0.01 respectively. Based on the following exchange rate scenarios, which are not forecasts, the impact on ...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

...levels, white blood cell (WBC) count and temperature and strain types of CDI. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to Vancocin (p=0.004) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains. ...

Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009

...f fiscal 2009. The Company attributes the lower fourth quarter sales growth rate to continued customer caution in a time of economic uncertainty. R&a...tology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

...d, randomized, placebo-controlled, multi-center trial and will seek to enroll an estimated 166 patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value = 0.005) in the previous Phase 3 study as a key measure of d...

Rapid heating prepares energy-saving zeolite for greater role in industrial separations

...lene. "Orthoxylene is slightly larger and should not pass readily through the pores. One would expect a perfect zeolite membrane to allow a permeation rate for paraxylene that is about two orders of magnitude higher than that of orthoxylene." "A considerable increase in paraxylene/orthoxylene selectivi...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...tients. The company presented data at the the 14(th) Congress of the European Hematology Association (EHA) in Berlin, Germany, showing an 81% response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease (MRD)(1). The patients included in this phase 2 clinical trial w...

International Milk Genomics & Human Health Symposium Speaker Program Announced

...aterials and daytime meals as well as a Monday evening reception. Sponsoring members of the International Milk Genomics Consortium can register at the rate of $400 through August 23, 2009 and $450 thereafter. Student rates and special hotel room rates also are available. Additional program information is ...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

...efficacy against bioterror agents such as tularemia, plague and melioidosis. In June, the company announced that Restanza demonstrated a 100% survival rate against an inhaled lethal dose of anthrax following a 14-day course of treatment in a second non-human primate study. The study was supported by the N...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... Company estimates that at its currently projected rate of net cash consumption, the net proceeds from thi...0. Interest on the Notes will accrue at a rate of ten percent (10%) per year. The Notes are conve...cted financial obligations that could increase the rate of our cash consumption, as well as risks detailed...